The Ipamorelin Difference Ipamorelin was introduced in 1998 by Raun and colleagues as, in their words, the first selective GH secretagogue a peptide that released GH with a potency comparable to the GHRPs but without the accompanying rise in ACTH and cortisol that characterizes GHRP-6 and GHRP-2
A study to assess efficacy and safety of add-on acetyl-l-carnitine and agmatine (rejiyana) with standard of care (soc) to validate visible changes in major depressive disorder a randomized controlled trial: revive trial
Ova and parasite examination targets Giardia and similar organisms, particularly after travel, camping, or well water exposure
Access the complete GLP-1 Pipeline Update table for May 2025
Shawe J, Ceulemans D, Akhter Z, Neff K, Hart K, Heslehurst N, et al